Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking forward to the return of friends!
Cw,
I liked this post in stock wits hope he is right , heck I don't know about this stuff...
https://stocktwits.com/BaronXXII/message/526985259
copy pasted here...DSMB review should kick off with an "open" session where RVVTF may be present (to answer questions, frame the report, etc.)
They can then move to a closed session to discuss data. A possible separate executive session (dsmb voting members only) to vote.
If anyone outside RVVTF attends the open session (silent partner?) word would likely spread swiftly. Watch for volume tomorrow.
(Yes. I know it's more realistic that that any silent partner would just wait until the dsmb answer before "doing" anything.)
ps. better if I mute the dummy here from stockwits who does not know me at all lol....
And Covid is far from Over hardly any testing now,test not working on new variants etc..
Of course it’s covid https://t.co/b5UE9sg9Ty
— Chris Turnbull (@EnemyInAState) May 8, 2023
Dear Experts:
— Marvin (@MarvinH2_G2) May 9, 2023
Blue is seasonal
Red is not seasonal https://t.co/O9E1zExEYH
Maybe he wasn't and isn't so interested in pursuing a sales product in support of the covid biosphere. .
Thank you Senor! Look forward to it!
D!¢$ are swinging in the. no pun intended. lol
Checking in and nice to see everyone still around,lets get some good data and a buyout offer,we didnt wait all this time
for nothing.
Allow me to be the first to kick off the festivities for tomorrow. MF will be schmoozing in the morning with the DSMB to get this product to market in the states. After analyzing the amazing data, there will be a slight leak as volume mounts in the afternoon. Within one week, MF drops a press release with the results of the trial. If Revive continues the trial with a partner, so be it. If they get bought out, good. If the trial was a flop, it is an expensive lesson and a few more years of hard work.
ps. Yes. I am the king of $2 lunches, Gator.
pps. I expect to hear from Rubber, Blue, All, Cool, Eco, Gator, Nosnibor and others as we start getting psyched up for the results of the 720 patients. One episode will certainly end within a week. Will another begin? It's anyone's guess. GLTA. (even Snoopy)
Been super busy, thanks for asking. Been doing the stealth possum thing, and the fox thing, hunting and been research a lot of over lapping health-bio-chemistry research and helping the world solve a food problem can cattle feed problem. And watching some new Netflix shows while we wait for $RVVTF major off to the Moon rally news. I do read & scan posts here....
"Averaging Down" is a common tool investors use that gets them into trouble after falling in love with their investments. WE have all been victims of that.
My question is --- if the trial is a failure, will the pps fall further. Or is failure already baked into the current price.
I've always felt that the CEO had fallen in love with his shrooms, and never really gave much priority to Bucillamine as a covid therapy. He had plenty of time to prepare for an FDA green light to proceed, and instead he dragged his feet early on. He did not have his ducks in a row for launching a covid trial. That was my red flag. And the FDA is no longer under pressure to approve EUA applications for covid. Slow you blow, snooze you loose.
Bullshite
The most apt response for that insipid garbage.
Why would someone waste their time posting stupid conspiracy theories and nonsense speculation on a stock they do like?
Sunk Cost Fallacy perfectly sums up this message board in three words. Perhaps you shouldn't have doubled and tripled down on it. But hey, we all screw up from time to time.
All I can say is Lol.....
why would someone waste there time posting stupid chit on a stock they dont like, managment probably more so ...in the stock forums that they do not like Lmao......
Get a fck ing life! :)
Poor little Gatorca. You've been wrong every step of the way. You and assic Warrior...wrong 100% of the time. Maybe it's time for the two of you to come clean with the six people left on the message board. Giovanni too. You guys are a true threesome. Rub-a-dub-dub three men in a tub!
Jack long covid complications will be with us forever. If buci can be used as a treatment so be it.
My stories lol your wacked out where the f uck u see that:)
By the way lol. Bmt know the Chit works but will the company show the best possible data lol...
ps, no your a washed up piece of chit lol.....
Gio,
All I can say is wtf lol...
I can't think of a more idiotic headline. Seriously. The freaking Center for Disease Control needs to open a probe into why a bunch of their infectious disease "experts" were infected by an incredibly transmissable respiratory virus while crowded together indoors maskless? 🤡💩💀 pic.twitter.com/cTorBNiQXu
— David Christopher 🏥🥼 🇵🇸 (@MLS_Dave) May 2, 2023
So that's what it's come to. Believers and nonbelievers.
Correct me if I'm wrong but isn't that what happens when you're close to the bottom?
I've had Covid once, for two weeks in the first half of October 2022. It came with conjunctivitis.
Alex- I'll take Bucillamine for $.20.
ps. Now Alex is gone.
pps. It was easier to laugh back then.
ppps. Good luck to all. (even Snoopy)
Sometime seems forever lol Cw :)
But anyways sure you seen this but chit I would be very happy even with 1B even.
Bucillamine Phase 3 clinical trial (NCT04504734) for #COVID-19 💊
— BITCOIN | DATA | LONG COVID (@kamtraders) May 4, 2023
By Revive Therapeutics $RVV $RVVTF
▪️DSMB meeting on May 10th, 2023 and will assess the efficacy of Bucillamine
▪️Revive expects to announce the recommendation of the DSMB meeting by May 17th, 2023.$veru $pfe pic.twitter.com/sP6M9RSec7
It will be nice to finally see the results after all this waiting and speculation. Good or bad, either way I can move on.
May 17th can not come soon enough. There is no excitement, based on the pps, as the longs hold and the rest of the world remains nonbelievers.
ps.It will be nice to finally see the results of the patients who took the higher dosage of Buccy. We have been waiting for quite some time.
A significant amount of asymptomatic Covid infections result in #LongCovid.
https://twitter.com/JacobBAguilar/status/1653916482655453185
ps. not sure why he follow me lol
pps. wait Cw ok he follows about %50 :) lol
Olympic gold medalist Tori Bowie dies aged 32. Just saying The BusS is moving. You will require it for the remainder of your lifetime. Or you GET SIDS
https://www.cnn.com/2023/05/03/sport/tori-bowie-death-track-and-field-spt-intl/index.html
What to know about XBB.1.16, the 'Arcturus' variant
A new Covid variant is spreading in the U.S., but will it cause a surge in cases?
XBB.1.16 — dubbed “Arcturus” on social media — is another descendant of omicron. It was first detected in early January and the majority of cases have been seen in India so far. It’s been steadily rising in the U.S. in recent weeks, although it still made up slightly less than 10% of new confirmed Covid cases as of Saturday, according to the Centers for Disease Control and Prevention.
Last week, the World Health Organization deemed XBB.1.16 a “variant of interest” as it continues to spread and outcompete other variants.
Ali Mokdad, a professor of global health at the University of Washington, said it’s still too early to predict what XBB.1.16 will do. But what he’s seen so far has been reassuring.
“We haven’t seen an increase in hospitalizations, we haven’t seen an increase in any of the indicators that make us worry,” Mokdad said.
Is XBB.1.16 more contagious?
Mokdad said that XBB.1.16 is gaining ground on the previously dominant strain in the U.S., called XBB.1.5.
That increased transmissibility appears to be due to the subvariant’s ability to avoid immune detection in the body.
“It can’t be spreading so fast unless it has some immune escape,” Mokdad said.
The virus has two ways of surviving, Mokdad said. One way is to be more infectious and evade immunity from previous infections or vaccinations, “which this one is doing,” he said. The other one is to become really deadly. “We haven’t seen that yet.”
Dr. Peter Chin-Hong, a professor of infectious disease at the University of California, San Francisco, said that aside from the increase in transmissibility, so far XBB.1.16 is not too different from XBB.1.5.
That means that “hopefully, it’s not going to be too different” in terms of how sick it makes people and how well the vaccines work.
What are the symptoms of XBB.1.16?
XBB.1.16 doesn’t appear to be making people sicker than earlier omicron strains, according to Dr. Mike Ryan, the executive director of the WHO’s health emergencies program.
“To my knowledge, we’re not seeing a different spectrum of symptoms or severity associated with this variant of interest,” Ryan said during a media briefing last week.
Some news reports have mentioned that XBB.1.16 infection causes a “new” symptom — conjunctivitis, or pink eye — though the WHO noted that this symptom was already known to be associated with Covid. As early as the spring of 2020 there were reports of itchy, sore eyes in Covid patients. In May 2020, the American Academy of Ophthalmologists noted that mild conjunctivitis could be a symptom of Covid.
"It's not a new symptom," but it may be more common than previously thought, Chin-Hong said.
Do vaccines work against XBB.1.16?
Mokdad said that labs haven’t yet determined how well the Covid vaccines work against XBB.1.16.
Chin-Hong said he wasn't particularly concerned about the vaccines.
"Because it's so similar to XBB.1.5, we think that vaccines will be fine," he said.
Last week, the Food and Drug Administration and the CDC said that older adults and immunocompromised individuals could get a second dose of the updated booster shot, which protects against an earlier omicron subvariant.
Why are there always new variants?
XBB.1.16 certainly won’t be the last new variant that emerges. The subvariant is yet another offshoot of the growing omicron family tree.
XBB.1.16 is a descendant of the XBB subvariant, which itself formed when two strains of omicron subvariant BA.2 combined, according to the WHO.
Already, two other XBB strains, XBB.1.9.1 and XBB.1.9.2 are also rising in the U.S. Together, the two strains account for about 11% of new cases, according to the CDC.
On Wednesday, the WHO's technical lead for Covid-19, Dr. Maria Van Kerkhove, said the XBB.1.9 strains are likely similar to what’s been seen with previous XBBs.
“This just indicates to us that the virus continues to evolve and it will continue to evolve because the virus is circulating pretty much unchecked,” Van Kerkhove said.
nbcnews.com
Ecomike
Whiners are in general losers!
RVVTF is for winners.??
I am confident that bucillamine holds great promise in combatting COVID. However, I do have some reservations about the CEO's ability to deliver on this potential. I am optimistic that the efficacy data will be positive, paving the way for the global distribution of bucillamine to every single person on Earth.
What You Need to Know
There is strong scientific evidence that antiviral treatment of outpatients at risk for severe COVID-19 reduces their risk of hospitalization and death.
The antiviral drugs nirmatrelvir with ritonavir (Paxlovid) , remdesivir (Veklury) and {? Bucillamine?} are the preferred treatments for eligible adult and pediatric patients who are at high risk for progression to severe COVID-19.
Clinicians should consider COVID-19 treatment in patients with mild-to-moderate COVID-19 who have one or more risk factors for severe COVID-19. Treatment must be started early to be effective.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html
Yes it looks like it. The only concerned I have is why they didn't go in the first place. What's behind the back door? They didn't have confidence. I heard Johnson and Johnson might be their partner. It's a perfect fit. Both of the CEO can't get anything done. LOL
O $h!^ if this pop in May that would be great. May go away is here.
So in other words, the company is following the exact path that was delineated back in Oct 2022?!?
My word!!!!!!!!
Expect a fresh round of heehawing IF the dsmb recommends continuing the study.
Ghosted in 3...2..1. lololsss
Thanks, I have never been a whiner LOL.
$RVVTF may end up outperforming the market this summer
Agreed. Continuing the study with hospitalizations as EP is lighting cash on fire and sacrificing time.
no matter the decision, it's going to take time and $$$ - probably just a matter of getting the data to where they can get a potential partner to look at what they've got and decide whether they (potential partner) want to fund further trials.
Continuation of the study is a death march.
Big pharma's plan (who controls the FDA) has always been to slow down or ruin any medical trials that threaten their cash cow: the vaccine. I have no doubt the FDA is going to tell Revive that they have to finish the 1000 patient trial and resubmit data, at which point they will take another year to decide to look at it, then another half a year to make a decision, at which point there will be less confirmed cases of Covid per year than small pox. We've been f__ked, gents. Big pharma strikes again. Guarantee they were handing out duffel bags of cash to stifle any competition.
That's a good catch. Unfortunately, that is the outcome we most desire. I think it may have to do with the endpoint switch back to hospitalizations. Unlike McDonalds, the FDA is not lovin it.
ps. Good data opens the door to so many pathways that it is hard not to get excited. I like the addition of symptom data, but I think Revive didn't accumulate exactly what the FDA wants so there still needs to be negotiations and discussions. This is where we could use some expertise.
Did you notice that they're down to two outcomes? continue the study OR halt due to significance not likely to be met. No longer looking at halting due to efficacy.
I'm very impressed with the detailed communication to SH !
Yes sir, very pleased and hopeful
NEWS OUT.
https://www.globenewswire.com/news-release/2023/05/02/2658886/0/en/Revive-Therapeutics-Announces-Data-Safety-Monitoring-Board-Meeting-Date-on-Phase-3-Clinical-Study-of-Bucillamine-in-the-Treatment-of-COVID-19.html?fbclid=IwAR3hk1InFM3Kt6I--6ciptfu6KhhmK0pV1Gwf2tpGsBoi7BWj4gWSuolhoE
I am pleasantly surprised the the data has already been submitted and the timelines are very soon. Let's see.
I wish I had know about and been able to get NAC over 60 years ago. Yes it helps, but Long Covid is about way more that "lung Issues". It helps with a family of health issues that use up the active L-Glutathione in the body. It is super safe and better than many mild asthma OTC products. I started taking it for RA about 6 years ago, before Covid19 arrived.
There is long laundry list of key vitamins, and supplements that help with all of the long issues, but most people are looking in the wrong place, namely the Medical Business/practice (That is why the call it practice, LOL) that is great at testing and surgery, but sucks at nutrition, and supplementation of poor diet and lifestyle issue assistance, for answers to complex bio-medical problems that may need daily over-site and expertise and experimental tweaking of each persons unique health situation to get them back to an optimal health and live style. AI may end being part of the solution.
But part of the problem is people's mind sets, who want one diagnosis and one pill and a miracle, and want keep drinking and eating and smoking junk...
Health officials warn irritating symptom may be returning with latest COVID strain
BY WILL CONYBEARE AND ADDY BINK - 05/01/23 7:05 AM ET
(KTLA) – A new coronavirus subvariant is starting to spread in the U.S. and, according to health experts, it could be causing an annoying symptom to return.
According to the Centers for Disease Control and Prevention, roughly 10% of all COVID cases reported last week were determined to be from the omicron-related XBB.1.16 subvariant, being referred to by some as Arcturus.
After first being reported in January, the World Health Organization declared XBB.1.16 a variant of interest in mid-April, The Hill reports.
The Los Angeles County Department of Public Health is warning residents that this omicron sub-strain of COVID-19 may come with an irritating symptom: conjunctivitis
Pandemic 3 years later: Has the COVID-19 virus won?
Commonly known as pink eye, health officials also reported that pink eye could be linked to COVID early in the pandemic. Then again last year, experts warned there could be a connection between the then-new omicron variant and itchy, irritated eyes.
Now, some health officials are reporting an increase in conjunctivitis cases nationwide.
That includes Los Angeles County, where the health department has warned that pink eye may be the newest possible symptom of COVID.
“Observational data suggests that people infected with XBB.1.16 may be more likely to experience conjunctivitis as a symptom of their COVID infection, along with more traditional COVID symptoms, such as fever, cough and shortness of breath,” the LA County Health Department said in a statement. “Historically, conjunctivitis was reported in 1 to 3% of COVID-19 cases.”
Conjunctivitis occurs when the lining that covers your eyelid and eyeball, the conjunctiva, becomes inflamed, optometrist Dr. Melanie Dombrowski tells Nexstar’s WGHP. Symptoms include eyes becoming pink or red, increased tear production, discharge from the eyes, and itching, irritation, or burning, according to the CDC.
Hair suddenly falling out in the shower? This might be why
Pink eye is common with respiratory infections like the cold and flu.
However, with the limited data available, the department said it is “too early to know with certainty” if XBB.1.16 is truly associated with higher rates of conjunctivitis.
“Residents should be aware that itchy, watery or red eyes may be a sign of a COVID-19 infection and these symptoms should not be simply dismissed as a result of pollen or seasonal allergies, especially if someone more vulnerable to severe illness could be exposed,” the Health Department said. “The fact that we are seeing new strains, with possibly new and different symptoms, tells us that COVID continues to evolve and the way we think about our protections should reflect what we know.”
You should talk to your doctor if you have pink eye as well as pain in the eyes, sensitivity to light, blurred vision, intense redness, symptoms that aren’t improving or get worse, or a weakened immune system, according to the CDC.
Older adults and individuals with underlying health conditions are encouraged to take extra precautions to avoid infection, which includes staying up to date on vaccinations, frequent hand washing, and staying home when feeling sick.
Though officials say Arcturus may be more effective at escaping immune response than other subvariants, it doesn’t appear any more severe.
Those guys have quality control supply chain market share and location presence.
I don’t blame you for trying to make lemonade from lemons but MF couldn’t monetize anything if his life depended on it. He’s skilled in golf. It’s a fun hobby
Let’s see how many days pass before he does something for all those suffering shareholders and monetize anything at all??
Ecomike
Fine as wine!
Haha ya mmhmmm. What’s the one glaring difference here? McDonalds and burger king have CEO’s that know how to type an email that doesn’t look like a 1st grader wrote it and can also tie their shoes which I don’t know if Frank can do. Oh and they also can likely check their egos at the door and do what’s best for their companies and shareholders. Frank denies any help including from individuals who have 10x the experience he does.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |